Polomar Health Services, Inc.
PMHS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PMHS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMHS
Polomar Health Services, Inc. (PMHS) is an early-stage company focused on developing and manufacturing new products, currently operating with a history of net losses and substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Market Cap
$8.5M
Cash Runway
—
Lead Asset
vigorair (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Polomar Health Services, Inc..
Polomar Health Services, Inc. (PMHS) is an early-stage company focused on developing and manufacturing new products, currently operating with a history of net losses and substantial doubt about its ability to continue as a going concern.
- The company has a history of net losses and expects to continue incurring losses for the foreseeable future [sec · filed 2024-10-04].
- As of June 30, 2024, accumulated deficit was $1,921,040 [sec · filed 2024-10-04].
- As of March 31, 2026, working capital was negative ($1,294,458) and the company does not have sufficient cash to fund operations for the next 12 months [sec_mda · as of 2026-06-01].
- The company's financial statements are prepared on a going concern basis, but there is substantial doubt about its ability to continue as a going concern [sec · filed 2024-10-04].
- Latest reported financials (as of 2026-06-30) show total revenue of $1.5M, net income of $0.2M, and shareholders' equity of -$1.1M [sec].
What works
- The company has generated some revenue, with latest reported total revenue of $1.5M as of 2026-06-30 [sec].
- The company has a net income of $0.2M in the latest reported period as of 2026-06-30 [sec].
What to weigh
- The company has a history of net losses and expects to continue incurring net losses for the foreseeable future [sec · filed 2024-10-04].
- As of March 31, 2026, the company has negative working capital of ($1,294,458) and does not have sufficient cash to fund operations for the next 12 months [sec_mda · as of 2026-06-01].
- The company's financial statements are prepared on a going concern basis, with substantial doubt about its ability to continue as a going concern [sec · filed 2024-10-04].
- The company has an accumulated deficit of $1,921,040 as of June 30, 2024 [sec · filed 2024-10-04].
From the filings
Quoted directly from source documents.
The company has a history of net losses and expects to continue incurring losses.
“We have a history of net losses and anticipate that we will continue to incur net losses for the foreseeable future.”
SEC filings · October 4, 2024
There is substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern.”
SEC filings · October 4, 2024
The company does not have sufficient cash to fund operations for the next 12 months.
“We currently do not have sufficient cash to fund our operations for the next 12 months”
SEC MD&A · June 1, 2026
The company has an accumulated deficit.
“As of June 30, 2024, we had an accumulated deficit of $1,921,040.”
SEC filings · October 4, 2024
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; financial statements prepared on that basis [sec · filed 2024-10-04].
- Insufficient liquidity — Negative working capital and insufficient cash to fund operations for next 12 months [sec_mda · as of 2026-06-01].
- History of losses — History of net losses and expectation of continued losses; accumulated deficit of $1,921,040 as of June 30, 2024 [sec · filed 2024-10-04].
- Financing risk — No assurance of raising additional capital on favorable terms or at all [sec · filed 2024-10-04].
What to watch
- Ability to raise additional capital or secure financing to fund operations beyond the next 12 months [sec_mda · as of 2026-06-01].
- Progress in generating sustainable revenue and achieving profitability [sec · filed 2024-10-04].
- Management's ability to retain key personnel and meet development/commercialization milestones [sec · filed 2024-10-04].
Sources: SEC filings · SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run Polomar Health Services, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Polomar Health Services, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $121K · Net income $200K
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Polomar Health Services, Inc.?
Polomar Health Services, Inc. (PMHS) is an early-stage company focused on developing and manufacturing new products, currently operating with a history of net losses and substantial doubt about its ability to continue as a going concern.
What is Polomar Health Services, Inc.'s lead drug candidate?
Polomar Health Services, Inc.'s most advanced tracked candidate is vigorair (Preclinical) for erectile dysfunction.
Who is the CEO of Polomar Health Services, Inc.?
Mr. Terrence M. Tierney J.D. is the chief executive officer of Polomar Health Services, Inc. (PMHS).
Where is Polomar Health Services, Inc. headquartered?
Polomar Health Services, Inc. (PMHS) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does Polomar Health Services, Inc. focus on?
Polomar Health Services, Inc. develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.